Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 microg) Following Single-Dose Administration to Healthy Subjects

Next Previous
Search
Trial Profile

A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 microg) Following Single-Dose Administration to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irdabisant (Primary) ; Donepezil; Modafinil
  • Indications Cognition disorders
  • Focus Pharmacodynamics
  • Sponsors Teva Pharmaceutical Industries

Most Recent Events

  • 02 Feb 2019 Results published in the British Journal of Clinical Pharmacology
  • 02 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
  • 18 Oct 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top